Mammalian orthoreovirus 3 (MRV‑3) is one of the three serotypes of mammalian orthoreoviruses, which are non‑enveloped double‑stranded RNA viruses of the genus Orthoreovirus (family Reoviridae).
Biology and distinctive features
MRV‑3 has a genome consisting of ten segments of double‑stranded RNA organised into large (L), medium (M) and small (S) segments. The S1 segment encodes the cell‑attachment protein σ1, and differences in this protein confer serotype specificity and receptor usage. The prototype MRV‑3 strain T3D (Dearing) was isolated from a mouse and is widely used in laboratory research. Virus entry involves receptor‑mediated endocytosis followed by protease‑driven uncoating in the gut or respiratory tract. Replication and assembly take place in cytoplasmic inclusion bodies, and progeny virions are released by cell lysis. MRV‑3 is stable in the environment because of its double‑layered capsid and can remain infectious in water and on surfaces. Infection occurs via faecal–oral or respiratory routes, and the virus replicates in the intestinal and respiratory epithelium before spreading to lymphoid tissues. In humans and most mammals infection is either asymptomatic or causes mild fever, rhinorrhoea or diarrhoea. Some strains, however, show neurotropism or pneumotropism and can cause more severe disease. There are no licensed vaccines or antiviral drugs; management is supportive.
Notable isolates and applications
Several MRV‑3 strains have been linked to zoonotic transmission. In 2006 a bat‑borne MRV‑3 known as Melaka virus caused acute respiratory disease in three family members in Malaysia after exposure to bats; a related Kampar virus was detected soon after. Another variant, Nelson Bay virus, was first isolated from a flying fox in Australia and later implicated in acute respiratory illness in humans. MRV‑3 strains have also been recovered from pigs, cattle and dogs, underscoring their broad host range. Beyond natural infections, MRV‑3 is notable for its oncolytic properties: the T3D strain preferentially replicates in cells with activated Ras signalling and has been developed into the investigational anticancer agent pelareorep (previously known as Reolysin), which is being tested in clinical trials for various solid tumours. Reassortment between MRV‑3 and other serotypes in experimental settings has provided insights into determinants of virulence and tissue tropism. Although usually benign, mammalian orthoreovirus 3 has revealed its capacity for respiratory disease and neuroinvasion and serves as a valuable model for virus-host interactions and oncolytic therapy development. Related Terms: Mammalian Orthoreovirus 1, Mammalian Orthoreovirus 2, Avian orthoreovirus, Nelson Bay virus, Pelareorep